Your browser is no longer supported. Please, upgrade your browser.
BPMC Blueprint Medicines Corporation daily Stock Chart
BPMC [NASD]
Blueprint Medicines Corporation
Index- P/E- EPS (ttm)-7.30 Insider Own0.40% Shs Outstand51.33M Perf Week4.99%
Market Cap3.49B Forward P/E- EPS next Y-6.53 Insider Trans-27.17% Shs Float51.33M Perf Month-14.76%
Income-347.70M PEG- EPS next Q-2.00 Inst Own96.50% Short Float6.71% Perf Quarter-8.81%
Sales66.50M P/S52.46 EPS this Y-34.80% Inst Trans0.29% Short Ratio4.79 Perf Half Y-13.49%
Book/sh9.43 P/B7.21 EPS next Y23.40% ROA-49.70% Target Price104.07 Perf Year-11.96%
Cash/sh9.42 P/C7.22 EPS next 5Y22.27% ROE-72.50% 52W Range60.60 - 102.98 Perf YTD-15.15%
Dividend- P/FCF- EPS past 5Y-32.50% ROI-77.80% 52W High-36.10% Beta1.58
Dividend %- Quick Ratio4.90 Sales past 5Y- Gross Margin- 52W Low8.59% ATR3.02
Employees221 Current Ratio4.90 Sales Q/Q734.60% Oper. Margin- RSI (14)44.97 Volatility3.83% 4.33%
OptionableYes Debt/Eq0.00 EPS Q/Q26.20% Profit Margin- Rel Volume0.74 Prev Close67.97
ShortableYes LT Debt/Eq0.00 EarningsFeb 13 BMO Payout- Avg Volume718.83K Price65.81
Recom1.70 SMA201.81% SMA50-9.71% SMA200-17.50% Volume368,499 Change-3.19%
Jan-28-20Initiated BMO Capital Markets Market Perform
Jan-27-20Initiated BMO Capital Markets Market Perform
Nov-06-19Upgrade Raymond James Outperform → Strong Buy $106 → $112
Oct-22-19Initiated JMP Securities Mkt Outperform $106
Oct-03-19Initiated H.C. Wainwright Buy $100
Sep-12-19Upgrade Raymond James Mkt Perform → Outperform
Aug-29-19Initiated Piper Jaffray Neutral $85
Aug-15-19Resumed Raymond James Mkt Perform
Jul-18-19Initiated Deutsche Bank Buy $110
May-23-19Resumed Goldman Buy $125
Apr-03-19Initiated Morgan Stanley Overweight $112
Sep-25-18Initiated Leerink Partners Outperform
Dec-11-17Reiterated Goldman Buy $82 → $99
Sep-29-17Initiated BTIG Research Buy $90
Apr-05-17Reiterated Wedbush Outperform $43 → $50
Mar-13-17Upgrade Goldman Neutral → Buy
Feb-15-17Initiated Morgan Stanley Overweight
Dec-14-16Initiated Jefferies Buy $40
May-27-16Initiated Raymond James Outperform $23
May-26-15Initiated Wedbush Outperform
Feb-20-20 03:45AM  Edited Transcript of BPMC earnings conference call or presentation 13-Feb-20 1:30pm GMT Thomson Reuters StreetEvents
Feb-19-20 06:16PM  3 Strong Buy Healthcare Stocks With Fast-Approaching Catalysts TipRanks
08:00AM  Blueprint Medicines to Present at Upcoming Investor Conferences PR Newswire
Feb-18-20 12:52PM  Ipsen writes down $725M after largest-ever acquisition, trial woes American City Business Journals
Feb-14-20 10:42AM  Blueprint Medicines (BPMC) Q4 Loss Narrows, Revenues Top Mark Zacks
Feb-13-20 10:31AM  Deciphera's NDA for GIST Drug Gets Priority Review From FDA Zacks
08:25AM  Blueprint Medicines (BPMC) Reports Q4 Loss, Tops Revenue Estimates Zacks
Feb-07-20 11:21AM  Blueprint Medicines' NDA for Avapritinib Gets Extended Review Zacks
07:32AM  The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns Benzinga
Feb-06-20 08:00AM  Blueprint Medicines Announces PDUFA Date Extension for New Drug Application of Avapritinib for the Treatment of Adults with Fourth-Line Gastrointestinal Stromal Tumor PR Newswire -5.39%
Feb-03-20 11:27AM  Andreas Halvorsen Trims Adaptive Biotechnologies Stake GuruFocus.com
Jan-30-20 11:04AM  Lilly's NDA for Selpercatinib Gets FDA's Priority Review Zacks
Jan-22-20 10:24PM  Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock PR Newswire -12.44%
08:25AM  The Daily Biotech Pulse: Johnson & Johnson Earnings, FDA Nod For Horizon Therapeutics, Slew Of Secondary Offerings Benzinga
Jan-21-20 04:01PM  Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock PR Newswire
Jan-16-20 04:59AM  Here's Why We're Not Too Worried About Blueprint Medicines's (NASDAQ:BPMC) Cash Burn Situation Simply Wall St.
Jan-13-20 08:00AM  Blueprint Medicines Announces 2020 Corporate Goals PR Newswire -8.00%
Jan-12-20 12:19PM  A Biotech Veteran Thinks He Can Undersell the Entire Drug Industry Barrons.com
Jan-11-20 06:45PM  How Did Blueprint Medicines Corporation (BPMC) Perform In Comparison to Hedge Fund Favorites in 2019? Insider Monkey
Jan-10-20 10:27AM  Blueprint Medicines' Ayvakit Gets FDA Nod for Rare Cancer Zacks
08:49AM  Blueprint prices new cancer drug at $32,000 per month MarketWatch
Jan-09-20 05:16PM  FDA approves Cambridge biotech's first-ever drug for cancer American City Business Journals
03:52PM  Blueprint Medicines Announces FDA Approval of AYVAKIT (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor PR Newswire
10:31AM  Blueprint Medicines Posts Data From NSCLC Study on Pralsetinib Zacks
Jan-08-20 08:00AM  Blueprint Medicines Announces Top-line Data for Pralsetinib and Initiates Rolling NDA Submission to FDA for the Treatment of Patients with RET Fusion-Positive Non-Small Cell Lung Cancer PR Newswire
Jan-07-20 10:26AM  Blueprint Medicines Initiates Dosing in Liver Cancer Study Zacks
Jan-06-20 08:00AM  CStone Pharmaceuticals and Blueprint Medicines Initiate Phase 1b/2 Clinical Trial of Fisogatinib in Combination with CS1001 for Patients with Hepatocellular Carcinoma PR Newswire
Dec-13-19 09:25AM  Blueprint Medicines (BPMC) Up More Than 30% YTD: Here's Why Zacks
Dec-12-19 09:56AM  Lilly Initiates Phase III Lung Cancer Study on RET Inhibitor Zacks
Dec-10-19 07:00AM  Biotech accelerator teams with investment firm for $210M fund raise American City Business Journals
Dec-09-19 09:55AM  Blueprint's (BPMC) Systemic Mastocytosis Study Data Impresses Zacks -10.33%
Dec-08-19 09:00AM  Blueprint Medicines Announces Initial Data from Phase 2 PIONEER Trial of Avapritinib in Patients with Indolent Systemic Mastocytosis Showing Activity at All Dose Levels Tested PR Newswire
Dec-07-19 07:59AM  Hedge Funds Love Medicines Corporation (BPMC) Way More Than These Stocks Insider Monkey
Dec-05-19 11:31AM  Why Is Blueprint Medicines (BPMC) Up 1.4% Since Last Earnings Report? Zacks
Dec-02-19 05:32AM  Is Blueprint Medicines Corporation's (NASDAQ:BPMC) CEO Being Overpaid? Simply Wall St. -6.98%
Nov-21-19 09:00AM  Blueprint Medicines (BPMC) Upgraded to Buy: What Does It Mean for the Stock? Zacks
Nov-14-19 08:00AM  Blueprint Medicines to Present at Jefferies 2019 London Healthcare Conference PR Newswire
Nov-06-19 11:24AM  Blueprint Medicines (BPMC) Q3 Earnings & Sales Top Estimates Zacks +5.11%
09:00AM  Blueprint Medicines to Present Initial Data from Phase 2 PIONEER Trial of Avapritinib in Patients with Indolent Systemic Mastocytosis at 61st ASH Annual Meeting and Exposition PR Newswire
Nov-05-19 08:35AM  Blueprint Medicines (BPMC) Reports Q3 Loss, Tops Revenue Estimates Zacks +5.04%
07:00AM  Blueprint Medicines Outlines Precision Therapy Research Vision, Provides Update on Discovery and Clinical-Stage Portfolio at R&D Day and Reports Third Quarter 2019 Financial Results PR Newswire
Nov-04-19 11:20AM  Eaton Vance Worldwide Health Sciences Fund Buys 2 Stocks GuruFocus.com
Oct-29-19 02:16PM  Were Hedge Funds Right About Selling Blueprint Medicines Corporation (BPMC)? Insider Monkey
08:00AM  Blueprint Medicines to Host R&D Day and Announce Third Quarter 2019 Financial Results on November 5, 2019 PR Newswire
Oct-28-19 08:00AM  Blueprint Medicines Announces FDA Intent to Split Avapritinib New Drug Application into Separate Submissions for PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST PR Newswire -13.70%
Oct-25-19 09:20AM  5 Biotech Stocks to Buy for a Strong Growth Prognosis InvestorPlace
Oct-16-19 11:34AM  Shareholders Are Thrilled That The Blueprint Medicines (NASDAQ:BPMC) Share Price Increased 153% Simply Wall St.
Oct-14-19 11:46AM  Blueprint Medicines' Avapritinib Grows to Curb Revenue Reliance Zacks
Oct-09-19 06:18PM  This Hedge Fund Returns 22% Annually, Here Are Its Latest Picks Insider Monkey
Sep-23-19 02:51PM  Edited Transcript of BPMC earnings conference call or presentation 1-Aug-19 12:30pm GMT Thomson Reuters StreetEvents
Sep-10-19 02:16PM  Does Blueprint Medicines Corporation (NASDAQ:BPMC) Have A Particularly Volatile Share Price? Simply Wall St.
Sep-09-19 04:39PM  Lilly's RET Inhibitor Shrinks Tumors in Lung Cancer Study Zacks -6.14%
Sep-05-19 09:16PM  4 Biotech Stocks With Big Catalysts in September Motley Fool
Aug-31-19 09:32AM  Why Is Blueprint Medicines (BPMC) Down 18.3% Since Last Earnings Report? Zacks
Aug-28-19 08:00AM  Blueprint Medicines to Present at Upcoming Investor Conferences in September PR Newswire
Aug-21-19 07:15PM  Blueprint Medicines Corp (BPMC) CEO and President Jeffrey W. Albers Sold $1.6 million of Shares GuruFocus.com
Aug-14-19 04:28PM  This Biotech Is On A Two-Day Sprint; Why An Analyst Prefers Its Rival Investor's Business Daily
Aug-13-19 10:19AM  Deciphera stock surges on gastrointestinal cancer drug success American City Business Journals
Aug-07-19 08:00AM  Blueprint Medicines Announces FDA Acceptance of New Drug Application for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST PR Newswire
Aug-06-19 03:45PM  The Top 5 Buys of the Eaton Vance Worldwide Health Sciences Fund GuruFocus.com
08:00AM  Blueprint Medicines to Present at 2019 Wedbush PacGrow Healthcare Conference PR Newswire
Aug-04-19 03:04PM  3 Lung Cancer Stocks That Could Soar in September Motley Fool
Aug-02-19 11:54AM  Blueprint Medicines (BPMC) Q2 Loss Widens, Sales Top Mark Zacks
12:24AM  Blueprint Medicines (BPMC) Q2 2019 Earnings Call Transcript Motley Fool
Aug-01-19 09:15AM  Blueprint Medicines (BPMC) Reports Q2 Loss, Tops Revenue Estimates Zacks -6.32%
07:00AM  Blueprint Medicines Reports Second Quarter 2019 Financial Results PR Newswire
Jul-25-19 08:00AM  Blueprint Medicines to Report Second Quarter 2019 Financial Results on Thursday, August 1, 2019 PR Newswire
Jul-18-19 04:01PM  Blueprint Medicines Announces European Medicines Agency Validation of Marketing Authorization Application for Avapritinib for the Treatment of PDGFR D842V Mutant GIST and Fourth-Line GIST PR Newswire
Jul-16-19 07:27AM  3 Soaring Biotech Stocks With More Fuel in the Tank Motley Fool
Jul-10-19 09:25AM  Here's Why Blueprint Medicines Stock Rose 75% in the First Half of 2019 Motley Fool
Jul-09-19 09:57AM  Has Blueprint Medicines Corporation (NASDAQ:BPMC) Got Enough Cash? Simply Wall St.
Jun-29-19 08:09AM  2 Stocks That Could Be the Next Biotech Buyouts Motley Fool
Jun-20-19 09:41AM  The Zacks Analyst Blog Highlights: Incyte, Blueprint Medicines, Verastem and uniQure Zacks
Jun-19-19 11:20AM  Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal Zacks
Jun-18-19 09:51AM  Cancer Therapy Stocks Soar After Pfizer Deal Investopedia
07:31AM  The Daily Biotech Pulse: PhaseBio Pumped Up, Eiger Exults On Breakthrough Therapy Designation, Biohaven Slips On Stock Sale Benzinga
07:09AM  Shares of cancer-therapy companies skyrocket after Pfizer acquisition news MarketWatch
Jun-15-19 06:00AM  Blueprint Medicines Presents Updated EXPLORER Trial Data for Avapritinib in Patients with Systemic Mastocytosis at 24th EHA Congress PR Newswire
Jun-14-19 06:09PM  Edited Transcript of BPMC earnings conference call or presentation 9-May-19 12:30pm GMT Thomson Reuters StreetEvents
08:45AM  Blueprint Medicines Submits New Drug Application to U.S. Food and Drug Administration for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST PR Newswire
Jun-10-19 09:39AM  Hedge Funds Have Never Been This Bullish On Blueprint Medicines Corporation (BPMC) Insider Monkey
Jun-08-19 09:30AM  Blueprint Medicines (BPMC) Up 7.3% Since Last Earnings Report: Can It Continue? Zacks
Jun-06-19 09:17AM  Life sciences VC firm Third Rock raises $770M in its largest round ever American City Business Journals +8.41%
Jun-05-19 11:44AM  Blueprint Medicines to File NDA for Avapritinib With FDA Zacks +5.96%
Jun-03-19 04:24PM  Who Are The Winners And Losers From The Year's Biggest Cancer Meeting? Investor's Business Daily
10:26AM  Blueprint Medicines' NDA for Avapritinib on Track for GIST Zacks
09:00AM  Blueprint Medicines' Highly Selective RET Inhibitor BLU-667 Shows Durable Anti-Tumor Activity in Patients with RET-Altered Cancers in Updated ARROW Trial Data Presented at ASCO 2019 PR Newswire
Jun-01-19 09:00AM  Blueprint Medicines Presents NAVIGATOR Trial Data in PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST at ASCO 2019 Supporting Planned Marketing Applications for Avapritinib PR Newswire
May-29-19 04:00PM  Blueprint Medicines to Present at Upcoming Investor Conferences in June PR Newswire
May-23-19 07:26PM  2 Top Stocks to Watch at ASCO 2019 Motley Fool
May-16-19 09:00AM  Blueprint Medicines Announces Data Presentations at ASCO and EHA Meetings from Registration-Enabling Clinical Trials of Avapritinib and BLU-667 Across Multiple Patient Populations PR Newswire +5.04%
May-15-19 10:16AM  3 Stocks With Big News Coming at ASCO 2019 Motley Fool
May-14-19 11:12AM  How Much is Blueprint Medicines Corporation's (NASDAQ:BPMC) CEO Getting Paid? Simply Wall St.
May-13-19 08:44AM  Blueprint Medicines (BPMC) Q1 Earnings & Sales Lag Estimates Zacks -11.34%
May-10-19 08:24AM  Blueprint Medicines (BPMC) Q1 2019 Earnings Call Transcript Motley Fool
May-09-19 08:35AM  Blueprint Medicines (BPMC) Reports Q1 Loss, Misses Revenue Estimates Zacks +7.22%
07:23AM  Blueprint Medicines: 1Q Earnings Snapshot Associated Press
07:00AM  Blueprint Medicines Reports First Quarter 2019 Financial Results PR Newswire
May-08-19 10:38AM  Drug/Biotech Stock Q1 Earnings on May 9: IONS, XLRN & More Zacks
08:00AM  Blueprint Medicines to Present at Bank of America Merrill Lynch 2019 Health Care Conference PR Newswire
Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma. It is also developing BLU-667, an orally available and potent inhibitor that targets RET, a receptor tyrosine kinase that is abnormally activated by mutations or translocations; and RET resistant mutants that would arise from treatment with first generation therapies. In addition, the company is developing BLU-782, an inhibitor targeting the kinase ALK2 for the treatment of fibrodysplasia ossificans progressiva, a rare genetic disease caused by mutations in the ALK2 gene, ACVR1. The company has collaboration and license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to discover, develop, and commercialize small molecule therapeutics targeting kinases. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Haviland KateChief Operating OfficerJan 10Option Exercise16.287,763126,38223,628Jan 14 04:47 PM
Demetri GeorgeDirectorJan 10Sale85.0056848,2802,462Jan 14 04:48 PM
Haviland KateChief Operating OfficerJan 10Sale85.167,763661,09715,865Jan 14 04:47 PM
Demetri GeorgeDirectorJan 07Sale80.591,705137,4063,030Jan 09 04:10 PM
Dorsch MarionChief Scientific OfficerDec 19Option Exercise37.114,600170,7064,600Dec 23 05:32 PM
Dorsch MarionChief Scientific OfficerDec 19Sale79.004,600363,4000Dec 23 05:32 PM
Boral Anthony L.Chief Medical OfficerDec 17Option Exercise8.8010,00088,00010,000Dec 19 04:38 PM
Boral Anthony L.Chief Medical OfficerDec 17Sale76.5710,000765,7130Dec 19 04:38 PM
Hurley ArielPrincipal Accounting OfficerDec 16Option Exercise1.87415776415Dec 18 04:33 PM
Hurley ArielPrincipal Accounting OfficerDec 16Sale75.0041531,1250Dec 18 04:33 PM
Hurley ArielPrincipal Accounting OfficerDec 04Sale77.2519214,8320Dec 06 04:32 PM
Albers Jeffrey W.CEO and PresidentNov 18Option Exercise2.5620,00051,26068,961Nov 20 05:07 PM
Albers Jeffrey W.CEO and PresidentNov 18Sale75.428,256622,65260,705Nov 20 05:07 PM
Hurley ArielPrincipal Accounting OfficerNov 15Option Exercise1.87415776415Nov 19 04:16 PM
Hurley ArielPrincipal Accounting OfficerNov 15Sale75.0041531,1250Nov 19 04:16 PM
Albers Jeffrey W.CEO and PresidentNov 08Sale74.5611,744875,63348,961Nov 20 05:07 PM
Albers Jeffrey W.CEO and PresidentOct 30Option Exercise1.8720,00037,40048,961Oct 30 04:32 PM
Hurley ArielPrincipal Accounting OfficerOct 17Option Exercise1.87415776415Oct 21 04:33 PM
Hurley ArielPrincipal Accounting OfficerOct 17Sale75.0041531,1250Oct 21 04:33 PM
Hurley ArielPrincipal Accounting OfficerSep 16Option Exercise1.87415776415Sep 18 04:24 PM
Hurley ArielPrincipal Accounting OfficerSep 16Sale78.1441532,4280Sep 18 04:24 PM
Boral Anthony L.Chief Medical OfficerAug 21Option Exercise8.808,70076,5608,700Aug 22 04:35 PM
Boral Anthony L.Chief Medical OfficerAug 21Sale80.018,700696,0870Aug 22 04:35 PM
Boral Anthony L.Chief Medical OfficerAug 20Option Exercise8.801,30011,4401,300Aug 22 04:35 PM
Boral Anthony L.Chief Medical OfficerAug 20Sale80.441,300104,5720Aug 22 04:35 PM
Haviland KateChief Operating OfficerAug 19Option Exercise16.28951,54715,960Aug 21 04:18 PM
Albers Jeffrey W.CEO and PresidentAug 19Option Exercise1.8720,00037,40048,961Aug 21 04:17 PM
Albers Jeffrey W.CEO and PresidentAug 19Sale81.7320,0001,634,66128,961Aug 21 04:17 PM
Haviland KateChief Operating OfficerAug 19Sale85.00958,07515,865Aug 21 04:18 PM
COATS LONNELDirectorAug 15Option Exercise15.0110,000150,10010,000Aug 19 04:34 PM
Hurley ArielPrincipal Accounting OfficerAug 15Option Exercise1.87415776415Aug 19 04:35 PM
Hurley ArielPrincipal Accounting OfficerAug 15Sale84.0241534,8680Aug 19 04:35 PM
COATS LONNELDirectorAug 15Sale82.4010,000824,0070Aug 19 04:34 PM
Hurley ArielPrincipal Accounting OfficerJul 19Option Exercise8.801151,012115Jul 23 06:23 PM
Hurley ArielPrincipal Accounting OfficerJul 19Sale100.0011511,5000Jul 23 06:23 PM
Haviland KateChief Operating OfficerJul 16Option Exercise16.2811,562188,22917,436Jul 18 07:53 PM
Haviland KateChief Operating OfficerJul 16Sale95.471,571149,98915,865Jul 18 07:53 PM
Hurley ArielPrincipal Accounting OfficerJul 15Option Exercise1.878301,552830Jul 17 04:26 PM
Hurley ArielPrincipal Accounting OfficerJul 15Sale94.9883078,8330Jul 17 04:26 PM
Boral Anthony L.Chief Medical OfficerJul 08Option Exercise8.8010,00088,00010,000Jul 10 04:45 PM
Boral Anthony L.Chief Medical OfficerJul 08Sale93.8810,000938,7560Jul 10 04:45 PM
Borisy AlexisDirectorJun 27Option Exercise32.7821,818715,08582,724Jul 01 07:23 PM
Borisy AlexisDirectorJun 27Sale92.0121,8182,007,44660,906Jul 01 07:23 PM
Rowland Charles A JrDirectorJun 20Option Exercise9.4611,818111,79811,818Jun 24 08:08 PM
Rowland Charles A JrDirectorJun 20Sale95.1511,8181,124,4620Jun 24 08:08 PM
Hurley ArielPrincipal Accounting OfficerJun 17Option Exercise4.711,4056,6121,405Jun 19 06:05 PM
Albers Jeffrey W.CEO and PresidentJun 17Option Exercise1.875,0009,35033,961Jun 19 06:07 PM
Dorsch MarionChief Scientific OfficerJun 17Option Exercise37.114,600170,7064,600Jun 19 06:08 PM
Haviland KateChief Operating OfficerJun 17Option Exercise25.6511,952306,59517,826Jun 19 06:08 PM
Haviland KateChief Operating OfficerJun 17Sale96.4611,9521,152,8705,874Jun 19 06:08 PM
Dorsch MarionChief Scientific OfficerJun 17Sale99.004,600455,4000Jun 19 06:08 PM
Albers Jeffrey W.CEO and PresidentJun 17Sale99.065,000495,30028,961Jun 19 06:07 PM
Hurley ArielPrincipal Accounting OfficerJun 17Sale98.221,405138,0020Jun 19 06:05 PM
Demetri GeorgeDirectorJun 17Sale98.501,136111,8904,735Jun 19 06:06 PM
Hurley ArielPrincipal Accounting OfficerJun 13Option Exercise1.871,6603,1041,660Jun 14 06:01 PM
Demetri GeorgeDirectorJun 13Sale90.0056851,1205,871Jun 17 05:12 PM
Lydon NicholasDirectorJun 13Sale90.3625,0002,259,000127,727Jun 17 05:11 PM
Hurley ArielPrincipal Accounting OfficerJun 13Sale90.001,660149,4000Jun 14 06:01 PM
Albers Jeffrey W.CEO and PresidentJun 12Option Exercise1.8720,00037,40048,961Jun 14 06:00 PM
Hurley ArielPrincipal Accounting OfficerJun 12Option Exercise1.878301,552830Jun 14 06:01 PM
Lydon NicholasDirectorJun 12Sale84.7725,0002,119,162152,727Jun 14 06:00 PM
Albers Jeffrey W.CEO and PresidentJun 12Sale84.7520,0001,694,90628,961Jun 14 06:00 PM
Hurley ArielPrincipal Accounting OfficerJun 12Sale85.001,07391,2050Jun 14 06:01 PM
Hurley ArielPrincipal Accounting OfficerMar 15Option Exercise1.87415776415Mar 19 05:23 PM
Albers Jeffrey W.CEO and PresidentMar 15Option Exercise1.8720,00037,40048,961Mar 19 05:25 PM
Albers Jeffrey W.CEO and PresidentMar 15Sale86.3920,0001,727,88428,961Mar 19 05:25 PM
Hurley ArielPrincipal Accounting OfficerMar 15Sale85.5541535,5030Mar 19 05:23 PM
Dorsch MarionChief Scientific OfficerMar 04Option Exercise37.112,30085,3532,300Mar 06 05:04 PM
Dorsch MarionChief Scientific OfficerMar 04Sale84.662,300194,7230Mar 06 05:04 PM
Haviland KateChief Operating OfficerMar 01Option Exercise23.1321,644500,63927,518Mar 05 05:31 PM
Haviland KateChief Operating OfficerMar 01Sale85.0521,6441,840,8225,874Mar 05 05:31 PM